Works matching DE "DECITABINE"

Results: 467

Epigenetic Anti‐Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue.

Published in:

Chemistry - A European Journal, 2022, v. 28, n. 26, p. 1, doi. 10.1002/chem.202200640

By:

Traube, Franziska R.;
Brás, Natércia F.;
Roos, Wynand P.;
Sommermann, Corinna C.;
Diehl, Tamara;
Mayer, Robert J.;
Ofial, Armin R.;
Müller, Markus;
Zipse, Hendrik;
Carell, Thomas

Publication type:

Article

Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects.

Published in:

Drug Metabolism Reviews, 2020, v. 52, n. 2, p. 258, doi. 10.1080/03602532.2020.1758712

By:

Silva, Ana Rita;
Dinis-Oliveira, Ricardo Jorge

Publication type:

Article

Proteomic Studies for the Investigation of γ-Globin Induction by Decitabine in Human Primary Erythroid Progenitor Cultures.

Published in:

Journal of Clinical Medicine, 2020, v. 9, n. 1, p. 134, doi. 10.3390/jcm9010134

By:

Theodorou, Andria;
Phylactides, Marios;
Katsantoni, Eleni;
Vougas, Kostas;
Garbis, Spyros D.;
Fanis, Pavlos;
Sitarou, Maria;
Thein, Swee Lay;
Kleanthous, Marina

Publication type:

Article

SNS‑032 combined with decitabine induces caspase‑3/gasdermin E‑dependent pyroptosis in breast cancer cells.

Published in:

Oncology Letters, 2025, v. 29, n. 4, p. N.PAG, doi. 10.3892/ol.2025.14948

By:

Chen, Yuxin;
Zhang, Danya;
Li, Jie;
Sun, Yue;
Wang, Jing;
Xi, Ling

Publication type:

Article

Demethylation drug 5-Aza-2'-deoxycytidine-induced upregulation of miR-200c inhibits the migration, invasion and epithelial-mesenchymal transition of clear cell renal cell carcinoma in vitro.

Published in:

Oncology Letters, 2021, v. 22, n. 3, p. N.PAG, doi. 10.3892/ol.2021.12923

By:

Jiang, Juan;
Yi, Bo;
Ding, Siqing;
Sun, Jian;
Cao, Wei;
Liu, Mengzi

Publication type:

Article

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD+ acute myeloid leukemia cells.

Published in:

Oncology Letters, 2021, v. 21, n. 5, p. N.PAG, doi. 10.3892/ol.2021.12658

By:

Liu, Yi;
Wei, Jing;
Liu, Jiaxin;
Ma, Weina;
Duan, Yanting;
Liu, Daihong

Publication type:

Article

Decitabine inhibits the proliferation of human T-cell acute lymphoblastic leukemia molt4 cells and promotes apoptosis partly by regulating the PI3K/AKT/mTOR pathway.

Published in:

Oncology Letters, 2021, v. 21, n. 5, p. N.PAG

By:

Zhang, Gang;
Gao, Xiaohui;
Zhao, Xiaoyan;
Wu, Haibing;
Yan, Minchao;
Li, Yuan;
Zeng, Hui;
Ji, Zhaoning;
Guo, Xiaojun

Publication type:

Article

Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine.

Published in:

Oncology Letters, 2019, v. 18, n. 5, p. 4457, doi. 10.3892/ol.2019.10788

By:

Pang, Yanbin;
Geng, Suxia;
Zhang, Hongyang;
Lai, Peilong;
Liao, Pengjun;
Zeng, Lingji;
Lu, Zesheng;
Weng, Jianyu;
Du, Xin

Publication type:

Article

Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.

Published in:

Oncology Letters, 2019, v. 17, n. 2, p. 2543

By:

Liu, Hongbin;
Hu, Yunshan;
Rimoldi, Rafael;
Von Hagt, Chloe;
Khong, Edmund W.C.;
Lee, Nora;
Flemming, Shaun;
Spencer, Andrew;
Dear, Anthony E.

Publication type:

Article

Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.

Published in:

2018

By:

Liu, Huan;
Cheng, Juan;
Zhao, Long;
Xu, Qian;
Xue, Mingming;
Zhang, Shuling;
Liu, Bei

Publication type:

Case Study

Role and mechanism of decitabine combined with tyrosine kinase inhibitors in advanced chronic myeloid leukemia cells.

Published in:

Oncology Letters, 2017, v. 14, n. 2, p. 1295, doi. 10.3892/ol.2017.6318

By:

LI-CAI JIANG;
JIAN-MIN LUO

Publication type:

Article

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.

Published in:

Oncology Letters, 2016, v. 11, n. 4, p. 2347, doi. 10.3892/ol.2016.4259

By:

KAI DING;
RONG FU;
HUI LIU;
NACHNANI, DEEPAK ANIL;
ZONG-HONG SHAO

Publication type:

Article

Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.

Published in:

Oncology Letters, 2016, v. 11, n. 2, p. 1521, doi. 10.3892/ol.2015.4052

By:

LILI XIANG;
JIAHE ZHOU;
WEIYING GU;
RONG WANG;
JIANG WEI;
GUOQIANG QIU;
JIANNONG CEN;
XIAOBAO XIE;
ZIXING CHEN

Publication type:

Article

Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.

Published in:

2016

By:

HUIFANG JIANG;
ZHONGLIN WU;
LI REN;
DIEHONG TAO;
HONGYAN TONG

Publication type:

Case Study

Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.

Published in:

Oncology Letters, 2015, v. 10, n. 2, p. 761, doi. 10.3892/ol.2015.3253

By:

MIKA HOSOKAWA;
MAI SAITO;
AIKO NAKANO;
SAKURA IWASHITA;
AYANO ISHIZAKA;
KUMIKO UEDA;
SEIGO IWAKAWA

Publication type:

Article

Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts.

Published in:

Oncology Letters, 2014, v. 8, n. 5, p. 1919, doi. 10.3892/ol.2014.2499

By:

BING WANG;
HONGBO LI;
RUI YANG;
SHUNCHANG ZHOU;
SHENGQUAN ZOU

Publication type:

Article

Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia.

Published in:

Molecular & Clinical Oncology, 2020, v. 12, n. 5, p. 475, doi. 10.3892/mco.2020.2006

By:

Pan, Yuming;
Zhang, Qiaoxia;
Deng, Xiaopeng;
An, Na;
Du, Xin;
Liu, Jiajun

Publication type:

Article

Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy.

Published in:

Molecular & Clinical Oncology, 2019, v. 11, n. 1, p. 91, doi. 10.3892/mco.2019.1858

By:

Maeda, Osamu;
Matsuoka, Ayumu;
Furukawa, Kazuhiro;
Miyahara, Ryoji;
Hirooka, Yoshiki;
Ando, Yuichi

Publication type:

Article

Palliative chemotherapy followed by methylation inhibitor in high-risk acute myeloid leukemia: An in vitro and clinical study.

Published in:

Molecular & Clinical Oncology, 2015, v. 3, n. 5, p. 1139, doi. 10.3892/mco.2015.605

By:

BINGJIE DING;
ZHIXIANG WANG;
XUEJIE JIANG;
XIAODONG LI;
CHUNLI WANG;
QINGXIU ZHONG;
LING JIANG;
MIN DAI;
YU ZHANG;
QI WEI;
FANYI MENG

Publication type:

Article

Characterization and Metabolism of Drug Products Containing the Cocaine-Like New Psychoactive Substances Indatraline and Troparil †.

Published in:

Metabolites (2218-1989), 2024, v. 14, n. 6, p. 342, doi. 10.3390/metabo14060342

By:

Manier, Sascha K.;
Mumber, Paula;
Zapp, Josef;
Eckstein, Niels;
Meyer, Markus R.

Publication type:

Article

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.

Published in:

Journal of Blood Medicine, 2015, v. 6, p. 25, doi. 10.2147/JBM.S64067

By:

Arthur, Christopher;
Cermak, Jaroslav;
Delaunay, Jacques;
Mayer, Jiří;
Mazur, Grzegorz;
Thomas, Xavier;
Wierzbowska, Agnieszka;
Jones, Mark M.;
Berrak, Erhan;
Kantarjian, Hagop

Publication type:

Article

Correction to: Decitabine/Cedazuridine: First Approval.

Published in:

2021

By:

Dhillon, Sohita

Publication type:

Correction Notice

Decitabine/Cedazuridine: First Approval.

Published in:

Drugs, 2020, v. 80, n. 13, p. 1373, doi. 10.1007/s40265-020-01389-7

By:

Dhillon, Sohita

Publication type:

Article

Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 623, doi. 10.2147/OTT.S276168

By:

Zhu, Zhipeng;
Lin, Sihao;
Wu, Xiaofang;
Xu, Jiuhua;
Li, Lulu;
Ye, Weipeng;
Li, Jiayi;
Huang, Zhengjie

Publication type:

Article

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 10143, doi. 10.2147/OTT.S272207

By:

Luo, Shuna;
Xu, Xiaofei;
Ye, Xingnong;
Zhu, Xiaoqiong;
Wu, Cai;
Chen, Dan;
Jin, Jingxia;
Zheng, Yan;
Zheng, Mengli;
Huang, Jian

Publication type:

Article

Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations.

Published in:

OncoTargets & Therapy, 2018, v. 11, p. 6863, doi. 10.2147/OTT.S161919

By:

Li, Limin;
Zhang, Xiaoqian;
Yu, Hongjuan;
Zhang, Mingwen;
Xu, Mengyuan;
Liu, Jie;
Fu, Yueyue;
Meng, Hongbin;
Lyu, Chengfang;
Li, Xiaoxia;
Zhou, Jin

Publication type:

Article

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms.

Published in:

OncoTargets & Therapy, 2017, v. 10, p. 5425, doi. 10.2147/OTT.S142561

By:

Xingnong Ye;
Dan Chen;
Yan Zheng;
Xiaoqiong Zhu;
Junkai Fu;
Jian Huang

Publication type:

Article

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients.

Published in:

OncoTargets & Therapy, 2015, v. 8, p. 2783, doi. 10.2147/OTT.S81093

By:

Yu Jing;
Xue Shen;
Qian Mei;
Weidong Han

Publication type:

Article

Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.

Published in:

Clinical Epigenetics, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13148-024-01677-z

By:

Zhang, Na;
Li, Hong;
Wang, Dan;
Wang, Zhen;
Zhu, Jia-Shi;
Chen, Kai;
Jiang, Hui;
Shao, Jing-Bo;
Cai, Cheng

Publication type:

Article

The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.

Published in:

Clinical Epigenetics, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13148-024-01627-9

By:

Li, Yi;
Mao, Xia;
Li, Mengyuan;
Li, Li;
Tong, Xiwen;
Huang, Lifang

Publication type:

Article

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics.

Published in:

Clinical Epigenetics, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13148-023-01596-5

By:

Javorniczky, Nora Rebeka;
Grishina, Olga;
Hund, Inga;
Pantic, Milena;
Pfeifer, Dietmar;
Schmoor, Claudia;
Thomas, Johanna;
Duyster, Justus;
Becker, Heiko;
Lübbert, Michael

Publication type:

Article

Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.

Published in:

Clinical Epigenetics, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13148-023-01500-1

By:

Tang, Zijiao;
Liu, Lu;
Borlak, Jürgen

Publication type:

Article

Gremlin-2 is a novel tumor suppressor that negatively regulates ID1 in breast cancer.

Published in:

Breast Cancer Research, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13058-024-01935-1

By:

Jung, Jiwoo;
Kim, Na Hui;
Park, Jayeon;
Lim, Dayeon;
Kwon, Minji;
Gil, World;
Jung, Suyeon;
Go, Minjeong;
Kim, Chaeeon;
Cheong, Ye Hwang;
Lee, Mee-Hyun;
Park, Hee Sun;
Eom, Yong-Bin;
Park, Sin-Aye

Publication type:

Article

Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting.

Published in:

Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01573-2

By:

An, Zhuo-Yu;
Zhang, Xiao-Hui

Publication type:

Article

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.

Published in:

Journal of Clinical Pharmacology, 2021, v. 61, n. 3, p. 349, doi. 10.1002/jcph.1742

By:

Ruiz‐Garcia, Ana;
Shaik, Naveed;
Lin, Swan;
Jamieson, Catriona;
Heuser, Michael;
Chan, Geoffrey

Publication type:

Article

Invitro drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymes.

Published in:

Xenobiotica, 2022, v. 52, n. 1, p. 1, doi. 10.1080/00498254.2021.2018628

By:

Säll, Carolina;
Fogt Hjorth, Christian

Publication type:

Article

Azacitidine in outpatient treatment - single center experience.

Published in:

Contemporary Oncology / Współczesna Onkologia, 2015, v. 19, n. 6, p. 467, doi. 10.5114/wo.2015.56653

By:

Rybka, Justyna;
Stefanko, Ewa;
Bogucka-Fedorczuk, Aleksandra;
Butrym, Aleksandra;
Poręba, Rafał;
Kuliczkowski, Kazimierz;
Wróbel, Tomasz

Publication type:

Article

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML.

Published in:

Cell Communication & Signaling, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12964-023-01278-y

By:

Li, Hongjiao;
Wang, Yi;
Feng, Shuang;
Chang, Kaijing;
Yu, Xinwen;
Yang, Fenfang;
Huang, Haozhe;
Wang, Yuanbo;
Li, Xiang;
Guan, Feng

Publication type:

Article

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

Published in:

BMC Cancer, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12885-015-1432-5

By:

Grishina, Olga;
Schmoor, Claudia;
Döhner, Konstanze;
Hackanson, Björn;
Lubrich, Beate;
May, Annette M.;
Cieslik, Caroline;
Müller, Michael J.;
Lübbert, Michael

Publication type:

Article

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.

Published in:

BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-69

By:

Mayer, Ji¿í;
Arthur, Christopher;
Delaunay, Jacques;
Mazur, Grzegorz;
Thomas, Xavier G.;
Wierzboawska, Agnieszka;
Ravandi, Farhad;
Berrak, Erhan;
Jones, Mark;
Yuhan Li;
Kantarjian, Hagop M.

Publication type:

Article

PIPELINE DRUGS.

Published in:: Oncology (08909091), 2020, v. 34, n. 10, p. 430
Publication type:: Article

Practical Dosing Considerations for Venetoclax [including commentary by Kerry A. Rogers].

Published in:

Oncology (08909091), 2019, v. 33, n. 9, p. 361

By:

Valla, Kelly

Publication type:

Article

Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway.

Published in:

Molecular & Cellular Biochemistry, 2017, v. 433, n. 1/2, p. 141, doi. 10.1007/s11010-017-3022-0

By:

Wang, Huihan;
Wang, Xiaobin;
Liao, Aijun;
Liu, Zhuogang

Publication type:

Article

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.

Published in:

Hematological Oncology, 2024, v. 42, n. 3, p. 1, doi. 10.1002/hon.3274

By:

Manda, Sudhir;
Anz, Bertrand M.;
Benton, Christopher;
Broun, E. Randolph;
Yimer, Habte A.;
Renshaw, John S.;
Geils, George;
Berdeja, Jesus;
Cruz, Jose;
Melear, Jason M.;
Fanning, Suzanne;
Fletcher, Luke;
Li, Yukun;
Duan, Yinghui;
Werner, Michael E.;
Potluri, Jalaja;
Pai, Madhavi V.;
Donnellan, William B.

Publication type:

Article

Myelodysplastic syndromes with ring sideroblasts.

Published in:

Hematological Oncology, 2023, v. 41, n. 4, p. 612, doi. 10.1002/hon.3125

By:

Bruzzese, Antonella;
Vigna, Ernesto;
Martino, Enrica Antonia;
Mendicino, Francesco;
Lucia, Eugenio;
Olivito, Virginia;
Bova, Carlo;
Barbato, Angelo;
Filippelli, Gianfranco;
Capodanno, Isabella;
Neri, Antonino;
Morabito, Fortunato;
Gentile, Massimo

Publication type:

Article

Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma.

Published in:

Hematological Oncology, 2023, v. 41, p. 313, doi. 10.1002/hon.3164_220

By:

Pal, I.;
Scotto, L.;
Sabzevari, A.;
Kinahan, C.;
Fox, T. E.;
Feith, D. J.;
Marchi, E.;
Loughran, T. P.;
O'Connor, O. A.

Publication type:

Article

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial.

Published in:

Hematological Oncology, 2020, v. 38, n. 4, p. 531, doi. 10.1002/hon.2755

By:

Zhou, Xinping;
Mei, Chen;
Zhang, Jin;
Lu, Ying;
Lan, Jianping;
Lin, Shengyun;
Zhang, Yuefeng;
Kuang, Yuemin;
Ren, Yanling;
Ma, Liya;
Wei, Juying;
Ye, Li;
Xu, Weilai;
Li, Kongfei;
Lu, Chenxi;
Jin, Jie;
Tong, Hongyan

Publication type:

Article

Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL).

Published in:

2019

By:

Cassin, Ramona;
Mattiello, Veronica;
Viltadi, Michela;
D'Aliberti, Deborah;
Piazza, Rocco;
Gambacorti‐Passerini, Carlo;
Gianelli, Umberto;
Neri, Antonino;
Cortelezzi, Agostino;
Reda, Gianluigi;
Gambacorti-Passerini, Carlo

Publication type:

Case Study

Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 5047, doi. 10.1007/s00432-022-04436-w

By:

Hong, Kyung U.;
Tagnedji, Afi H.;
Doll, Mark A.;
Walls, Kennedy M.;
Hein, David W.

Publication type:

Article

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.

Published in:

Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 12, p. 3089, doi. 10.1007/s00432-019-03031-w

By:

Xiu, Cai;
Li, Xiao;
Wu, Lingyun;
Xu, Feng;
He, Qi;
Zhang, Zheng;
Wu, Dong;
Song, Luxi;
Su, Jiying;
Zhou, Liyu;
Zhao, Youshan;
Tao, Ying;
Chang, Chunkang

Publication type:

Article